Clinical Trial Update: Idelalisib+Obinutuzumab in Patients With Relapsed/Refractory Follicular Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating idelalisib in combination with obinutuzumab for relapsed or refractory follicular lymphoma was terminated, and results have been post…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma

Drugs mentioned

• Idelalisib (idelalisib)
• Obinutuzumab (obinutuzumab)

Snippet

Sponsor: Fondazione Italiana Linfomi - ETS | Conditions: Follicular Lymphoma | Phase 2 | Status: TERMINATED | Results posted: 2024-11-21